Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xilio Therapeutics (XLO) Current Deferred Revenue (2024 - 2025)

Xilio Therapeutics' Current Deferred Revenue history spans 2 years, with the latest figure at $69.3 million for Q3 2025.

  • For Q3 2025, Current Deferred Revenue rose 165.63% year-over-year to $69.3 million; the TTM value through Sep 2025 reached $69.3 million, up 165.63%, while the annual FY2024 figure was $13.5 million, N/A changed from the prior year.
  • Current Deferred Revenue for Q3 2025 was $69.3 million at Xilio Therapeutics, down from $70.9 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $70.9 million in Q2 2025 and bottomed at $13.5 million in Q4 2024.